Tech Support

TECHNICAL SUPPORT
+1.800.674.3430

This line is for technical support.
For General Enquiries please click General Contact

NASH Day Webinar: Overcoming Challenges in NAFLD/NASH Preclinical Modeling

Wednesday June 12th, 2019 10:30am EST

Presented by Dr Guodong Zhang this webinar focuses on new solutions to overcome preclinical NAFLD/NASH research challenges. Explore the pros and cons of a range of preclinical NASH models, as well as alternative liver disease evaluation methods, to help optimize and progress your drug development programs.

NEW WHITE PAPER: Key Applications of Syngeneic Models to Maximize I/O Translatability

Learn how to optimize syngeneic translatability through proof of concept and target engagement studies. Read our new White Paper to explore how panels of syngeneic models are used to evaluate new single agent and combination regimens, uncover biomarkers of I/O response, and discover common PD markers for predicting population response.

WEBINAR: Assessing Immunotherapy Toxicity in NHPs

Wednesday June 25, 2019 10:30am EST

Presented by Dr Thomas Scullion this webinar focuses on using NHPs for the preclinical assessment of immunotherapy toxicity. Explore how clinical trials are de-risked by evaluating immuno-safety early in drug discovery, and how to incorporate exploratory toxicology NHP studies into your preclinical programs.

SYMPOSIUM: Cellular Therapies in Oncology and Beyond: from Drug Development to Clinical Applications

June 27th, 2019 - Janssen Research Campus, Beerse, Belgium

Join our oncology cell therapy symposium, jointly organised with Janssen Pharmaceutica and hosted at their research campus in Beerse, Belgium, to explore the latest developments in the field, and how cellular therapies are being applied from the early stages of drug discovery through to improving patient clinical response.

New US Site Grand Opening Promotion - Free Arm on Syngeneic Studies!

To celebrate the Grand Opening of our new San Diego site we're offering a free arm on subcutaneous syngeneic model studies. You can choose from any validated syngeneic model offered at our US location for studies with at least 5 arms and n=10/arm.

Preview our ADA 2019 posters

We're presenting posters on a unique translational NASH model at the ADA Scientific Sessions this year. Preview our latest data on NASH induction in the dysmetabolic MS-NASH mouse (formerly FATZO), and accelerated disease induction resulting in a model featuring both severe fibrosis and dysmetabolism.

BREAKING NEWS: CrownBio and Hubrecht Organoid Technology Announce Strategic Partnership

Partnership combines breakthrough organoid technology with the world’s largest PDX collection to create a unique patient-derived translational research platform.

New Accelerated and Exacerbated Liver Fibrosis Model for NASH Preclinical Studies

Advance your NASH therapeutics with the inherently dysmetabolic, obese, and diabetic MS-NASH mouse (formerly FATZO). Learn more about standard NASH induction on Western diet plus fructose, as well as accelerated disease progression and exacerbated pathology with CCl4 administration. Explore new CCl4 data, including improved lipid profile and NAS score with OCA treatment.

ON DEMAND WEBINAR: How to Optimize Preclinical Diabetes Studies using Stress Free Methods in NHPs

Presented by Dr Andrew Puca this webinar focuses on novel techniques for optimizing preclinical diabetes research with spontaneously diabetic NHPs. Learn more about continuous glucose monitoring and the banana tolerance test, and how reducing invasiveness and stress leads to improved study data and clinical outcomes.

Download our 15 AACR Posters

We're presenting 15 posters at AACR 2019. Preview our topics now, covering a wide variety of preclinical oncology and immuno-oncology platforms including cancer organoids as drug screening tools, prostate cancer and sarcoma PDX panels, and a wide variety of novel I/O models and immunoprofiling data.

Accelerate Your In Vivo Immunotherapy Development with High Throughput MuScreenTM-Syngeneic Screening

Test your surrogate or cross-reactive I/O agents rapidly and efficiently with our large-scale syngeneic immunotherapy screen. MuScreen-Syngeneic is open for enrollment now, on a first come first served basis.

Clarity with
Crown

Recognize your next clinical candidate when you see it.

Our Translational Platforms enable our clients to identify the right patients for the right treatment. Having models which more accurately mimic human disease and population dynamics are key to successfully translating promising compounds into successful clinical candidates, whether treating Oncology or Diabetes related diseases.

Magnify your
insights

Understand the mechanisms of disease.

Our scientific acumen and experience will give you a deeper understanding of not just the pharmacological profile of your compound, but more importantly, a clear understanding of which compounds to progress into the clinic. Take a look at our publications to get a deeper understanding of the depth of our scientific expertise.

Begin with the
end insight

Connecting science to patients.

We help our clients solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease by answering some of the most challenging questions about human biology.

CVMD

Models of Obesity

obesity-img.jpg

CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More

Oncology

Oncology Databases

databases-img.jpg

Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More

CVMD

Diabetes Models

oncoexpress-img.jpg

Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

May 8, 2019

NASH Induction with CCl4

Learn more about NASH induction through CCl4 administration, and the advantages of inducing NASH in a dysmetabolic background.

Read More

May 8, 2019

NASH Induction with CCl4

Learn more about NASH induction through CCl4 administration, and the advantages of inducing NASH...

Read More

May 7, 2019

Combination Therapies and Tumor Homograft Models

Learn more about using tumor homograft models to assess oncology combination regimens, including...

Read More

April 25, 2019

Large-Scale Immunotherapy Screening: How and Why?

Learn more about the need for large-scale cancer immunotherapy screens and the different...

Read More

April 16, 2019

5 Criteria for Choosing a Contract Research Organization

Contract research organizations (CROs) vary in capability, quality, experience, cost, and ease...

Read More

April 3, 2019

New Analysis, Model ID, and Modeling Technologies at AACR 2019

In Atlanta this week we’re presenting data on our new analysis platforms and preclinical...

Read More

Upcoming Events


May 31 - June 4, 2019 | Booth #13101

ASCO Annual Meeting 2019

Chicago, IL


June 4, 2019

Geneva Immunology Day

Geneva, Switzerland


June 7-11, 2019 | Booth #2119

ADA 79th Scientific Sessions

San Francisco, CA


June 11 - 13, 2019

Antibody Engineering & Therapeutics Europe

Amsterdam, The Netherlands


International NASH Day, June 12, 2019, 10:30 EST

Webinar: Overcoming Challenges in NAFLD/NASH Preclinical Modeling